Biomarker News and Research

RSS

A biomarker is a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease. A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule.

PBS-Bio announces three new contracts to develop cancer therapy

In an industry that faces increasing challenges in delivering new drugs to patients, Predictive Biomarker Sciences (PBS-Bio) today announced three new contracts aimed at bringing new medicines to the marketplace.

20 Oct 2010

$More studies needed on bisphosphonates therapy and fracture risk$

More studies needed on bisphosphonates therapy and fracture risk

On October 13, the Food and Drug Administration published a warning to doctors and patients about an increased risk of thigh fractures with a widely used group of bone-strengthening drugs called bisphosphonates. This warning was much awaited in the light of a report published in the American Journal of Bone and Mineral Research in September titled "Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research."

20 Oct 2010

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Inspiration Biopharmaceuticals, Inc. announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.

20 Oct 2010

New ADNI-GO effort enables researchers to study Alzheimer's disease

Volunteers in New York, NY are being sought for a clinical study examining the subtle changes that may take place in the brains of older people many years before overt symptoms of Alzheimer's disease (AD) appear. Researchers at Columbia University Medical Center are specifically looking for people with the very earliest complaints of memory problems that affect their daily activities. The study will follow participants over time, using imaging techniques specifically developed to advance research into changes taking place in the structure and function of the living brain, as well as biomarker measures found in blood and cerebrospinal fluid.

19 Oct 2010

Metabolon announces publication of metabolic analysis of biochemical changes in CF primary lung epithelial cells

Metabolon, Inc., the leader in global metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Profiling Reveals Biochemical Pathways and Biomarkers Associated with Pathogenesis in Cystic Fibrosis Cells", in the Journal of Biological Chemistry.

18 Oct 2010

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

18 Oct 2010

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

At the American Academy of Ophthalmology (AAO) Middle East-Africa Council of Ophthalmology (MEACO) Joint Meeting today, researchers report progress on two top eye disease challenges treating advanced "dry" age-related macular degeneration, and preventing blindness in people with diabetes.

18 Oct 2010

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company leveraging its proprietary BHT-DNA platform to develop targeted autoimmune disease treatments, today announced that it will present at the 26th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and 15th Annual Conference of Rehabilitation in MS in Gothenburg, Sweden, data from its concluded Phase 2 clinical trial showing that baseline blood plasma anti-MBP (myelin basic protein) profiles identify responders to BHT-3009 treatment.

14 Oct 2010

Metabolon announces publication of Ablation of Locus Coeruleus in Tg-2576 transgenic mice

Metabolon, Inc., leaders in global metabolomics, biomarker discovery and biochemical analysis, announces the publication of "Ablation of the Locus Coeruleus (LC) Increases Oxidative Stress in Tg-2576 Transgenic But Not Wild-type Mice" in the International Journal of Alzheimer Disease.

14 Oct 2010

Acceleron announces ACE-031 Phase 1b study results

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced preliminary results from a Phase 1b study to assess the safety, tolerability and pharmacodynamic (PD) activity of ACE-031 following multiple ascending doses in healthy postmenopausal volunteers.

14 Oct 2010

BIOBASE introduces Genome Trax Next Generation Sequencing solution

BIOBASE announced today that it is entering the Next Generation Sequencing (NGS) market with the launch of a new solution. Genome Trax™ enables researchers to identify genome variations of functional significance by mapping them to known elements such as gene regulatory sites and disease-linked mutations.

13 Oct 2010

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

A subset of lung cancer patients seem to live longer and experience delays in disease progression when a new drug that targets a cancer-associated molecule called MET is added to treatment with erlotinib, the results of a double-blind Phase-II trial show.

11 Oct 2010

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

11 Oct 2010

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

ArQule, Inc. today announced the presentation of final results from a Phase 2 clinical trial in non-small cell lung cancer (NSCLC) of ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, at the annual meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Combination of MET and erlotinib delays lung cancer progression: Study

11 Oct 2010

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Lee National Denim Day event raises $4-$5 million fund for breast cancer

It didn't matter if they were faded, straight leg, boot cut or distressed; hundreds of thousands of people put on jeans with Felicity Huffman to celebrate Lee National Denim Day. The event has become one of the largest single-day fundraisers for breast cancer, and through $5 donations, has raised an estimated $4-$5 million for the Women's Cancer Programs of the Entertainment Industry Foundation (EIF), bringing the 15-year total to nearly $85 million.

8 Oct 2010

Biomarker News and Research

Further Reading

PBS-Bio announces three new contracts to develop cancer therapy

More studies needed on bisphosphonates therapy and fracture risk

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

New ADNI-GO effort enables researchers to study Alzheimer's disease

Metabolon announces publication of metabolic analysis of biochemical changes in CF primary lung epithelial cells

Neogenix to present NPC-1C antibody data at ASCO Annual Meeting

Researchers report progress on two eye disease challenges at AAO-MEACO 2010 Joint Meeting

Bayhill to present BHT-3009 Phase 2 clinical trial data at European Committee Congress

Metabolon announces publication of Ablation of Locus Coeruleus in Tg-2576 transgenic mice

Acceleron announces ACE-031 Phase 1b study results

BIOBASE introduces Genome Trax Next Generation Sequencing solution

New targeted therapy adds benefit to erlotinib in some patients with advanced lung cancer

Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer

ArQule announces ARQ 197 Phase 2 clinical trial results at ESMO annual meeting

Combination of MET and erlotinib delays lung cancer progression: Study

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

Lee National Denim Day event raises $4-$5 million fund for breast cancer

Adeona completes enrollment in Part 2 CopperProof-2 clinical study

New biomarker could aid in accurate diagnosis of Alzheimer's disease

Optical technology shows potential for prescreening patients at high risk for lung cancer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News